IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Mohanraj, Lathika ^a   Kim, Ho Seong ^b   Li, Wei ^c   Cai, Qing ^a   Kim, Ki Eun ^d   Shin, Hye Jung ^e   Lee, Yong Jae ^b   Lee, Woo Jung ^b   Kim, Jung Hyun ^b   Oh, Youngman ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c Biocure Pharma LLC   (United States)

^d CHA University   (South Korea)

^e National Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ADIPONECTIN GENE; ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DOWN REGULATION; FEMALE; GENE; GENE OVEREXPRESSION; GLUCOSE TRANSPORT; GLUCOSE TRANSPORTER 4 GENE; HUMAN; HUMAN CELL; ICAM 1 GENE; IN VITRO STUDY; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3 GENE; INSULIN RECEPTOR SUBSTRATE 1 GENE; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; MALE; MONOCYTE CHEMOTACTIC PROTEIN 1 GENE; OBESITY; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; VCAM 1 GENE; WAIST CIRCUMFERENCE;

ADIPOCYTES; ADIPOSITY; ADOLESCENT; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; C-REACTIVE PROTEIN; CELL ADHESION; CHEMOKINE CCL2; CHILD; CYTOKINES; DISEASE PROGRESSION; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MACROPHAGES; MONOCYTES; NF-KAPPA B; OBESITY; PROTEOLYSIS; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873857197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055084     Document Type: Article

References (52)

1. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM, (2010) Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303: 242-249.
2. Dubuc PU, (1976) The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25: 1567-1574.
3. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, et al. (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107: 671-674.
4. Neels JG, Olefsky JM, (2006) Inflamed fat: what starts the fire? J Clin Invest 116: 33-35.
5. Hwa V, Oh Y, Rosenfeld RG, (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787.
6. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, et al. (2007) Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 92: 1319-1325.
7. Spilcke-Liss E, Friedrich N, Dorr M, Schminke U, Volzke H, et al. (2011) Serum Insulin-like Growth Factor-I and its Binding Protein 3 in their Relation to Intima Media Thickness: Results of the Study of Health in Pomerania (SHIP). Clin Endocrinol (Oxf).
8. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R, et al. (2004) The IGF-I system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm IGF Res 14: 91-96.
9. Kielczewski JL, Hu P, Shaw LC, Li Calzi S, Mames RN, et al. (2011) Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am J Pathol 178: 1517-1528.
10. Oh Y, Muller HL, Lamson G, Rosenfeld RG, (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268: 14964-14971.
11. Han J, Jogie-Brahim S, Harada A, Oh Y, (2011) Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-kappaB signaling. Cancer Lett 307: 200-210.
12. Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, et al. (2011) Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-kappaB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem 286: 17898-17909.
13. Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, et al. (2010) Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 285: 30233-30246.
14. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, et al. (1990) Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 71: 797-805.
15. AM HZ, Collard TJ, Malik K, Hicks DJ, Paraskeva C, et al. (2006) Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int J Oncol 29: 1279-1286.
16. Jogie-Brahim S, Feldman D, Oh Y, (2009) Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 30: 417-437.
17. Bang P, Brismar K, Rosenfeld RG, (1994) Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab 78: 1119-1127.
18. Maury E, Noel L, Detry R, Brichard SM, (2009) In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 94: 1393-1400.
19. Skolnik EY, Marcusohn J, (1996) Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Factor Rev 7: 161-173.
20. Olson AL, Pessin JE, (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16: 235-256.
21. Matsuzawa Y, (2010) Adiponectin: a key player in obesity related disorders. Curr Pharm Des 16: 1896-1901.
22. Buckway CK, Wilson EM, Ahlsen M, Bang P, Oh Y, et al. (2001) Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab 86: 4943-4950.
23. Ouwens DM, Sell H, Greulich S, Eckel J, (2010) The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 14: 2223-2234.
24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
25. Odegaard JI, Chawla A, (2011) Alternative macrophage activation and metabolism. Annu Rev Pathol 6: 275-297.
26. Dalmas E, Clement K, Guerre-Millo M, (2011) Defining macrophage phenotype and function in adipose tissue. Trends Immunol 32: 307-314.
27. Martinez FO, Gordon S, Locati M, Mantovani A, (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177: 7303-7311.
28. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, et al. (1996) Insulin resistance and body fat distribution. Diabetes Care 19: 287-291.
29. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, et al. (1990) Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16: 484-490.
30. Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, et al. (1994) Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246.
31. Guzik TJ, Mangalat D, Korbut R, (2006) Adipocytokines- novel link between inflammation and vascular function? J Physiol Pharmacol 57: 505-528.
32. Kim HS, Ali O, Shim M, Lee KW, Vuguin P, et al. (2007) Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res 61: 159-164.
33. Williams AC, Smartt H, AM HZ, Macfarlane M, Paraskeva C, et al. (2007) Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ 14: 137-145.
34. Silha JV, Gui Y, Murphy LJ, (2002) Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab 283: E937-945.
35. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR, (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45: 91-100.
36. Palau N, Rebuffat SA, Altirriba J, Piquer S, Hanzu FA, et al. (2012) Role of IGFBP-3 in the regulation of beta-cell mass during obesity: adipose tissue/beta-cell cross talk. Endocrinology 153: 177-187.
37. Gatenby VK, Kearney MT, (2010) The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin Ther Targets 14: 1333-1342.
38. Schuler-Luttmann S, Monnig G, Enbergs A, Schulte H, Breithardt G, et al. (2000) Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol 20: E10-15.
39. Maile LA, Holly JM, (1999) Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res 9: 85-95.
40. Bunn RC, Fowlkes JL, (2003) Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 14: 176-181.
41. Bang P, Fielder PJ, (1997) Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology 138: 3912-3917.
42. Firth SM, Baxter RC, (1995) The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res 6: 223-229.
43. Ballerini MG, Ropelato MG, Domene HM, Pennisi P, Heinrich JJ, et al. (2004) Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab 17: 749-757.
44. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
45. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR, (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56: 16-23.
46. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, et al. (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7: 496-507.
47. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, et al. (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7: 485-495.
48. Brand K, Page S, Rogler G, Bartsch A, Brandl R, et al. (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97: 1715-1722.
49. Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, et al. (2000) Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148: 23-30.
50. Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M, Evans PC, (2010) Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 118: 593-605.
51. Tikellis C, Jandeleit-Dahm KA, Sheehy K, Murphy A, Chin-Dusting J, et al. (2008) Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis 199: 55-64.
52. Jialal I, Devaraj S, (2001) Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 116 (Suppl):: S108-115.